De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: the initial Iranian experience

Background: Anti-CD20 are among the high-efficacy DMTs commonly used in treating multiple sclerosis (MS). Long-term safety data on anti-CD20s are limited. There is convincing evidence of hypogammaglobulinemia in the long-term use of anti-CD20s, raising the likelihood of infection. Accordingly, there...

Description complète

Détails bibliographiques

Auteurs principaux:	Sepideh Paybast, Nasim Rezaeimanesh, Abdorreza Naser Moghadasi
Format:	Artigo
Langue:	Inglês
Publié:	Babol University of Medical Sciences 2025-10-01
Collection:	Caspian Journal of Internal Medicine
Sujets:	anti-cd20 b cell depleting monoclonal antibody de-escalation relapse remitting multiple sclerosis rrms
Accès en ligne:	http://caspjim.com/article-1-4079-en.pdf
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!